Core Insights - The stock of Basestone Pharmaceuticals (02616) rose over 9% in early trading, reaching a price of 5.98 HKD with a trading volume of 20.69 million HKD [1] - Singapore's Government Investment Corporation (GIC) increased its stake in Basestone Pharmaceuticals by 1.7955 million shares at a price of 5.4692 HKD per share, totaling approximately 9.82 million HKD [1] - Following this acquisition, GIC's total shareholding in Basestone Pharmaceuticals increased to approximately 10.5 million shares, representing a 7.11% ownership [1] Company Developments - GIC has steadily increased its stake in Basestone Pharmaceuticals from 5.49% on August 18 to 6.00% on October 13, and now to 7.11% within a span of less than three months, indicating strong international capital recognition of the company's long-term value [1] - The company's internal confidence is also reflected in the actions of its CEO, Yang Jianxin, and other key executives, who have repeatedly purchased company shares since the second half of this year [1]
基石药业-B早盘涨超9% GIC继续增持公司股份 持股比例已突破7%